SST and neuroendocrine neoplasm: Lutetium-177 (<sup>177</sup>Lu) dotatate is a type of peptide receptor radioligand therapy (PRRT) using radiolabeled somatostatin for patients with progressive somatostatin receptor-positive gastrointestinal neuroendocrine tumors.